CT-guided laser therapy in resistant human tumors: Phase I clinical trials

R. A. Gatenby, W. H. Hartz, F. E. Engstrom, J. S. Rosenblum, N. D. Hammond, H. B. Kessler, P. J. Moldofsky, M. R. Clair, E. Unger, G. J. Broder

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Photodynamic therapy was performed on ten tumors in patients who did not respond to initial therapy and for whom no additional conventional therapy was available. A sensitizing agent (hematoporphyrin derivative [HpD]) was injected directly into each tumor under computed tomographic (CT) guidance to deliver high concentrations to the tumor and to minimize systemic toxicity. Three to 6 days after the injection, a clear Teflon sheath catheter was placed into the tumor under CT guidance. The tumor was exposed to red light (630-nm wavelength) through laser fiberoptics inserted in the sheath. The initial investigation confirmed the technical feasibility of CT-guided photodynamic therapy by means of intratumoral HpD injections and laser exposure through fiberoptics inserted in sheath catheters. The toxicity from a single treatment was minor, and the tumor response was encouraging.

Original languageEnglish (US)
Pages (from-to)172-175
Number of pages4
Issue number1
StatePublished - 1987

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'CT-guided laser therapy in resistant human tumors: Phase I clinical trials'. Together they form a unique fingerprint.

Cite this